LACTOLOGY FOUNDATION

Alosetron (ATC A03AE01) is a potent, selective 5‑HT3 receptor antagonist used in a very narrow indication for severe diarrhea‑predominant irritable bowel syndrome (IBS‑D) in women, but carries significant gastrointestinal toxicity concerns and essentially no established safety data in breastfeeding, so use during lactation is generally discouraged or reserved for exceptional cases with strict specialist oversight.medpedia.framar+4

Pharmacological class and indication

Alosetron belongs to ATC group A03AE01: drugs for functional bowel disorders acting on serotonin (5‑HT3) receptors in the gastrointestinal tract. It is indicated only for women with severe, chronic IBS‑D who have not responded to conventional therapy and who have no structural or biochemical gastrointestinal abnormalities. In routine practice it is not a first‑line agent and is usually prescribed under a restricted use/monitoring program due to safety issues.drugbank+6

Mechanism of action

Alosetron is a highly selective antagonist of the serotonin 5‑HT3 receptor located on enteric neurons and vagal afferents in the gut. By blocking these receptors, it reduces visceral pain signaling, slows colonic transit, and decreases urgency and stool frequency in IBS‑D. This modulation of motility and sensitivity improves IBS symptoms in a subset of carefully selected female patients.ncbi.nlm.nih+7

General toxicity profile

From a toxicological perspective, alosetron is primarily limited by serious gastrointestinal adverse reactions rather than systemic organ toxicity. The most important toxic effects include severe constipation, intestinal obstruction, ischemic colitis, perforation, and toxic megacolon, some cases of which have been fatal or required urgent surgery. Because of these risks, treatment must be discontinued immediately if constipation, rectal bleeding, new or worsening abdominal pain, or bloody diarrhea occur, and patients must be educated to recognize early warning signs.mayoclinic+4

Common and dose‑related adverse effects

The most frequently reported adverse reaction is constipation, which can occur early in treatment and may be dose‑dependent. Other commonly described reactions include abdominal discomfort or pain, nausea, rectal discomfort, and less often headache, dizziness, or rare cardiovascular events such as hypertension. In clinical trials, constipation occurred in a clinically relevant proportion of treated patients and was the main reason for discontinuation.clinician+6

Serious gastrointestinal toxicity

Ischemic colitis is a specific and idiosyncratic risk associated with alosetron therapy, presenting with abdominal pain, rectal bleeding, and bloody diarrhea. Post‑marketing surveillance identified cases of severe ischemic colitis, complicated constipation, obstruction, perforation, and toxic megacolon, leading to temporary withdrawal of the drug from some markets and subsequent reintroduction with strict risk‑management protocols. These events can occur at standard doses and sometimes early in therapy, so close monitoring and rapid drug discontinuation at first symptoms are essential.clevelandclinicmeded+5

Contraindications and high‑risk groups

Alosetron is contraindicated in patients with a history of chronic or severe constipation and in those with intestinal obstruction, stricture, toxic megacolon, gastrointestinal perforation, or adhesions that may predispose to obstruction. It should not be used in patients with a history of ischemic colitis, inflammatory bowel disease, diverticulitis with complications, or hypercoagulable states predisposing to colonic ischemia. Caution is advised in older adults, who may have an increased risk of severe constipation and ischemic complications.boehringer-ingelheim+4

Drug–drug interaction considerations

Alosetron is metabolized primarily by hepatic cytochrome P450 enzymes, including CYP1A2 and to a lesser extent CYP2C9 and CYP3A4, so strong inhibitors of these isoenzymes (for example certain fluoroquinolones, macrolides, azole antifungals, and some antidepressants) may increase exposure and toxicity risk. Interaction databases list a limited number of strongly clinically significant interactions and a larger number of moderate interactions, reflecting mainly pharmacokinetic modulation or additive constipating effects. Co‑administration with other agents that markedly slow gastrointestinal motility or cause constipation (such as opioids, anticholinergics, or certain calcium channel blockers) may further increase the risk of severe constipation, obstruction, or toxic megacolon and should be approached cautiously or avoided.medpedia.framar+3

Use in pregnancy

There are no adequate, well‑controlled studies of alosetron use in pregnant women, and animal data are insufficient to exclude potential risks. Given its non‑life‑saving indication and the significant risk of severe maternal gastrointestinal toxicity, alosetron is generally not recommended in pregnancy, and safer alternative strategies for IBS‑D should be prioritized. Any off‑label use during pregnancy would require individualized risk–benefit assessment in consultation with a specialist, but such use is rarely justified.wikipedia+3

Pharmacokinetics relevant to lactation

Alosetron is well absorbed orally and undergoes extensive first‑pass metabolism, with a relatively low absolute bioavailability and a plasma half‑life on the order of hours rather than days. It exhibits moderate plasma protein binding and is cleared predominantly by hepatic metabolism, with urinary and fecal excretion of metabolites. From a theoretical standpoint, these characteristics suggest that transfer into breast milk might be limited in absolute amount, but this cannot be assumed safe in the absence of direct measurements or clinical experience in nursing dyads.mayoclinic+3

Lactation safety and theoretical risks

There are no dedicated clinical studies evaluating alosetron concentrations in human breast milk or its effects in breastfed infants, and major breastfeeding guidance resources do not list alosetron among medicines considered compatible with lactation. In principle, most orally administered drugs appear in breast milk in small amounts, often below 1% of the maternal dose, but drugs with serious idiosyncratic toxicity and no therapeutic indication in infants warrant greater caution. Given the potential for severe constipation, ischemic colitis, and intestinal obstruction in adults, inadvertent exposure of a neonate or young infant—even at low relative doses—raises concern for gastrointestinal adverse effects or altered motility, especially in preterm or medically fragile infants.franciscanhealth+3

Practical lactation recommendations

Because of the absence of lactation data, non‑essential indication, and serious GI toxicity profile, most conservative toxicology‑lactology approaches would categorize alosetron as “avoid during breastfeeding” or “use only if no safer alternatives and breastfeeding interruption is acceptable.” In a hypothetical scenario where alosetron is deemed absolutely necessary for a breastfeeding woman with severe, refractory IBS‑D, a shared decision‑making process should cover: consideration of alternative IBS‑D therapies with established lactation safety, potential temporary cessation of breastfeeding (with milk expression and discard), and close clinical monitoring of the infant for changes in stool pattern, abdominal distension, or blood in stools if exposure occurs. Consultation with a specialist lactation pharmacology service (such as a national medicines in lactation center) is advisable before initiating therapy in a nursing mother.infantrisk+3

Toxicology‑lactology summary for A03AE01

Within A03AE01, alosetron is currently the representative agent and is characterized by a narrow IBS‑D indication, significant GI toxicity (notably ischemic colitis and severe constipation), and lack of evidence regarding safety during breastfeeding. For lactating women, the balance of benefit and risk is generally unfavorable, and safer alternatives for IBS‑D management should be preferred whenever possible. If, exceptionally, alosetron is used, strict adherence to prescribing restrictions, early detection of adverse GI symptoms, and specialist guidance on breastfeeding management are mandatory.kegg+8